TRASTUZUMAB DERUXTECAN
Information current as at: 1 July 2026
PBAC meeting date: November 2026
Submission Details
- Brand name:
-
- Enhertu®
- Form and strength:
-
- Powder for I.V. infusion 100 mg
- Submission sponsor:
- ASTRAZENECA PTY LTD
- Condition/indication:
(therapeutic use) -
- Breast cancer
- Listing requested:
- To request listing of trastuzumab deruxtecan for the treatment of patients with human epidermal growth factor receptor 2 (HER2) positive early breast cancer who have pathological residual disease in the breast and/or axillary lymph nodes following neoadjuvant therapy (i.e. therapy given prior to surgery) at a high-risk of disease recurrence.
- Funding program:
- PBS Section 100 (Efficient Funding of Chemotherapy)
- Request authority level:
- Authority Required (Telephone/Online)
- PBAC Submission type:
- Change to existing listing (–)
- Comment:
- --
- Other PBAC consideration:
- --
Progress Details
-
Submission received for: - November 2026 PBAC meeting
-
2Opportunity for consumer comment:
- Open 22/07/2026 and close 16/09/2026 (see PBS Website)
-
3PBAC meeting:
- Has not yet occurred
-
4PBAC outcome published:
- Pending PBAC outcome (see PBAC Outcomes)
-
5Lodgement of required documentation:
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
PBAC Outcome
Case ID
a1314
Page last updated
23 July 2026
v.9.19